# COmmunity Patients at Risk of Viral Infections Including SARS-CoV-2

> **NCT04858451** · PHASE2 · TERMINATED · sponsor: **Thirty Respiratory Limited** · enrollment: 88 (actual)

## Conditions studied

- COPD
- Bronchiectasis

## Interventions

- **DRUG:** RESP301

## Key facts

- **NCT ID:** NCT04858451
- **Lead sponsor:** Thirty Respiratory Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-01
- **Primary completion:** 2022-12-22
- **Final completion:** 2023-02-08
- **Target enrollment:** 88 (ACTUAL)
- **Why stopped:** Study stopping criteria were met. A safety event has occurred which was classified as an SAE and was related to the study intervention.
- **Last updated:** 2025-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04858451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04858451, "COmmunity Patients at Risk of Viral Infections Including SARS-CoV-2". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04858451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*